• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ensysce Biosciences, AST SpaceMobile, IGM Biosciences And Other Big Stocks Moving Lower On Friday

    3/31/23 11:28:17 AM ET
    $AEHR
    $ANVS
    $ARCE
    $ASTS
    Electrical Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEHR alert in real time by email

    U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording losses in today’s session.

    • Gorilla Technology Group Inc. (NASDAQ:GRRR) shares fell 66% to $4.0150.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) tumbled 23.6% to $5.19. Ensysce Biosciences posted a Q4 loss of $1.52 per share.
    • AST SpaceMobile, Inc. (NASDAQ:ASTS) shares dropped 21.2% to $5.04 after the company posted a wider Q4 loss.
    • Annovis Bio, Inc. (NYSE:ANVS) fell 20.4% to $16.00. Annovis Bio received interim analysis for sample size re-estimation for its Phase 3 clinical trial for treatment of early Parkinson's disease.
    • Disc Medicine Opco Inc (NASDAQ:IRON) dropped 15% to $18.69 after the company reported full year 2022 financial results.
    • Zura Bio Limited (NASDAQ:ZURA) declined 14.4% to $13.55.
    • Aehr Test Systems (NASDAQ:AEHR) fell 12.5% to $32.56 following Q3 results.
    • Nikola Corporation (NASDAQ:NKLA) dipped 12.5% to $1.22 after the company announced pricing for a $100 million common stock offering.
    • IGM Biosciences, Inc. (NASDAQ:IGMS) dropped 12% to $14.98 after the company reported Q4 financial results.
    • Target Hospitality Corp. (NASDAQ:TH) fell 11.3% to $13.68. Northland Capital Markets maintained Target Hospitality with an Outperform and lowered the price target from $26 to $20.
    • Arco Platform Limited (NASDAQ:ARCE) dropped 9.7% to $11.17. Arco Platform posted Q4 revenue of R$679.3 million, up 47.4% year over year.
    • TROOPS, Inc. (NASDAQ:TROO) fell 7.7% to $3.23.
    • Avidity Biosciences, Inc. (NASDAQ:RNA) dropped 6.6% to $15.70. Avidity Biosciences announced its decision to conclude the Phase 1/2 MARINA trial with the 38 participants enrolled at 1mg ,2mg and 4mg/kg of AOC 1001 and not to move forward with the 8 mg/kg dose in DM1.
    • Studio City International Holdings Limited (NYSE:MSC) fell 5.8% to $6.31.
    • Korea Electric Power Corporation (NYSE:KEP) dropped 5.5% to $6.91.

    Check This Out: Ethereum Trades Above This Key Level; Hedera, Rocket Pool Among Top Gainers

    Get the next $AEHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEHR
    $ANVS
    $ARCE
    $ASTS

    CompanyDatePrice TargetRatingAnalyst
    Atrium Therapeutics Inc.
    $RNA
    3/11/2026$25.00Overweight
    Wells Fargo
    Aehr Test Systems
    $AEHR
    3/2/2026Mkt Perform → Outperform
    William Blair
    Zura Bio Limited
    $ZURA
    2/9/2026$15.00Outperform
    Wedbush
    AST SpaceMobile Inc.
    $ASTS
    1/13/2026$105.00Buy → Neutral
    B. Riley Securities
    AST SpaceMobile Inc.
    $ASTS
    1/7/2026$45.60Sector Perform → Sector Underperform
    Scotiabank
    Aehr Test Systems
    $AEHR
    12/17/2025$29.00Buy
    Lake Street
    Gorilla Technology Group Inc.
    $GRRR
    12/11/2025$31.00Overweight
    Cantor Fitzgerald
    AST SpaceMobile Inc.
    $ASTS
    11/24/2025$45.60Sector Underperform → Sector Perform
    Scotiabank
    More analyst ratings

    $AEHR
    $ANVS
    $ARCE
    $ASTS
    SEC Filings

    View All

    Annovis Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Annovis Bio, Inc. (0001477845) (Filer)

    3/16/26 5:06:04 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Gorilla Technology Group Inc.

    144 - Gorilla Technology Group Inc. (0001903145) (Subject)

    3/16/26 12:23:44 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-K filed by Annovis Bio Inc.

    10-K - Annovis Bio, Inc. (0001477845) (Filer)

    3/13/26 5:15:44 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEHR
    $ANVS
    $ARCE
    $ASTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Yao Huiwen exercised 40,000 in-the-money shares at a strike of $0.06, increasing direct ownership by 842% to 44,750 units (SEC Form 4)

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    3/12/26 6:30:05 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    Director Scott Geoffrey Gates gifted 5,104 shares, decreasing direct ownership by 9% to 52,864 units (SEC Form 4)

    4 - AEHR TEST SYSTEMS (0001040470) (Issuer)

    3/10/26 8:20:55 PM ET
    $AEHR
    Electrical Products
    Industrials

    SEC Form 4 filed by Director Nirula Ajay

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/5/26 6:30:17 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEHR
    $ANVS
    $ARCE
    $ASTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/2/26 5:55:03 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Larson Keith R bought $50,000 worth of shares (625 units at $80.00) (SEC Form 4)

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    12/29/25 6:00:02 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    Director Larson Keith R bought $50,064 worth of shares (715 units at $70.02) (SEC Form 4)

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    12/17/25 6:00:10 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    $AEHR
    $ANVS
    $ARCE
    $ASTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gorilla Technology & Yotta Sign Landmark AI Infrastructure Deal, Establishing Major Position in India's Sovereign AI Buildout

    - Agreement includes an AI infrastructure deployment in India of approx. 640 high-performance servers with more than 5,000 GPUs for AI workloads- This deployment is expected to contribute more than $500 million in revenue over the next five yearsLondon, United Kingdom--(Newsfile Corp. - March 16, 2026) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence, IoT technology and data centres, today announced that it has signed binding agreements with Yotta Data Services Private Limited ("Yotta") to deploy GPU infrastructure in India of approximately 640 high-perf

    3/16/26 8:30:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

    MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced business updates and reported financial results for the fiscal year 2025. In 2025, Annovis achieved a significant milestone in its clinical development program with the initiation of a pivotal Phase 3 clinical trial in early AD. The year was largely dedicated to the activation of clinical sites and the enrollment of participants across the United States. The Company als

    3/16/26 7:30:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Studio City International Holdings Limited Announces Filing of Annual Report on Form 20-F for Fiscal Year 2025

    MACAU, March 13, 2026 (GLOBE NEWSWIRE) -- Studio City International Holdings Limited (NYSE:MSC) ("Studio City" or the "Company"), a world-class integrated resort located in Cotai, Macau, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025. The annual report can be accessed under the Annual Reports section on the Company's investor relations website at https://ir.studiocity-macau.com/annual-reports. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests can be made through the Information Request section

    3/13/26 7:50:13 AM ET
    $MLCO
    $MSC
    Hotels/Resorts
    Consumer Discretionary

    $AEHR
    $ANVS
    $ARCE
    $ASTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Atrium Therapeutics with a new price target

    Wells Fargo initiated coverage of Atrium Therapeutics with a rating of Overweight and set a new price target of $25.00

    3/11/26 8:36:38 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aehr Test Systems upgraded by William Blair

    William Blair upgraded Aehr Test Systems from Mkt Perform to Outperform

    3/2/26 8:27:16 AM ET
    $AEHR
    Electrical Products
    Industrials

    Wedbush initiated coverage on Zura Bio Limited with a new price target

    Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    2/9/26 6:54:14 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEHR
    $ANVS
    $ARCE
    $ASTS
    Leadership Updates

    Live Leadership Updates

    View All

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

    1/21/26 8:50:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Target Hospitality Announces Appointment of Chief Accounting Officer

    THE WOODLANDS, Texas, Jan. 13, 2026 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality," "Target" or the "Company") (NASDAQ:TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today announced the hiring of Cyril J. Hahamski as Chief Accounting Officer. Mr. Hahamski will oversee the Company's accounting function, including external financial reporting, internal controls, and management reporting. This appointment will further strengthen Target's internal capabilities as the Company continues to pursue a robust pipeline of growth opportunities.  Concurrent with Mr. Hahamski's appointment, Jason Vlacich w

    1/13/26 6:45:00 AM ET
    $TH
    Hotels/Resorts
    Consumer Discretionary

    $AEHR
    $ANVS
    $ARCE
    $ASTS
    Financials

    Live finance-specific insights

    View All

    Target Hospitality Announces 2025 Results Highlighting Significant Advancement of Strategic Growth Initiatives as Expanding Customer Demand Accelerates Momentum

    Announces new $129 million, 1,400-bed, multi-year committed revenue contract supporting large-scale West Texas power generation and data center development ("West Texas Power Community")Announces new $23 million, 400-bed, multi-year committed revenue contract supporting the development of essential natural gas power generation capacity near Pecos, Texas ("Pecos Power Community") Supporting over $740 million of multi-year contracts announced since February 2025, focused on diversified and high-value strategic WHS marketsTHE WOODLANDS, Texas, March 11, 2026 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality", "Target" or the "Company") (NASDAQ:TH), one of North America's largest pro

    3/11/26 6:45:00 AM ET
    $TH
    Hotels/Resorts
    Consumer Discretionary

    Target Hospitality Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call Schedule

    THE WOODLANDS, Texas, March 4, 2026 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality", "Target" or the "Company") (NASDAQ:TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Wednesday, March 11, 2026. The Company has also scheduled a conference call for Wednesday, March 11, 2026, at 9:00 am Eastern Time (8:00 am Central Time) to discuss the results. The conference call will be available by live webcast through the Investors section of Target Hospitality's website at www.TargetHospit

    3/4/26 6:45:00 AM ET
    $TH
    Hotels/Resorts
    Consumer Discretionary

    AST SpaceMobile Provides Business Update and Fourth Quarter and Full Year 2025 Results

    Reported revenue of $70.9 million for the full year 2025, driven by mobile network operator partners and the U.S. Government Secured over $1.2 billion in aggregate contracted revenue commitments from partners Successfully completed unfolding of BlueBird 6, the largest commercial communications array ever deployed in low Earth orbit, expected to greatly exceed 120 Mbps peak data speeds Continued orbital launch campaign with encapsulation of BlueBird 7 at Cape Canaveral in February and expected launch during March, with additional launches expected every one to two months on average to reach goal of 45 to 60 satellites in orbit by end of 2026 AST SpaceMobile, Inc. ("AST SpaceMobile")

    3/2/26 4:32:00 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    $AEHR
    $ANVS
    $ARCE
    $ASTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    12/6/24 9:25:12 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by AST SpaceMobile Inc.

    SC 13D/A - AST SpaceMobile, Inc. (0001780312) (Subject)

    11/20/24 9:59:14 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care